Delatorre Edson, Silva-de-Jesus Carlos, Couto-Fernandez José Carlos, Pilotto Jose H, Morgado Mariza G
1 Laboratório de AIDS & Imunologia Molecular, Instituto Oswaldo Cruz-FIOCRUZ , Rio de Janeiro, Brazil .
2 Hospital Geral de Nova Iguaçu , Rio de Janeiro, Brazil .
AIDS Res Hum Retroviruses. 2017 Jan;33(1):68-73. doi: 10.1089/AID.2016.0159. Epub 2016 Aug 5.
Antiretroviral (ARV) resistance mutations in human immunodeficiency virus type 1 (HIV-1) infection may reduce the efficacy of prophylactic therapy to prevent mother-to-child transmission (PMTCT) and future treatment options. This study evaluated the diversity and the prevalence of transmitted drug resistance (TDR) in protease (PR) and reverse transcriptase (RT) regions of HIV-1 pol gene among 87 ARV-naive HIV-1-infected pregnant women from Rio de Janeiro, Brazil, between 2012 and 2015. The viral diversity comprised HIV-1 subtypes B (67.8%), F1 (17.2%), and C (4.6%); the circulating recombinant forms 12_BF (2.3%), 28/29_BF, 39_BF, 02_AG (1.1% each) and unique recombinants forms (4.5%). The overall prevalence of any TDR was 17.2%, of which 5.7% for nucleoside RT inhibitors, 5.7% for non-nucleoside RT inhibitors, and 8% for PR inhibitors. The TDR prevalence found in this population may affect the virological outcome of the standard PMTCT ARV-regimens, reinforcing the importance of continuous monitoring.
1型人类免疫缺陷病毒（HIV-1）感染中的抗逆转录病毒（ARV）耐药性突变可能会降低预防母婴传播（PMTCT）的预防性治疗效果以及未来的治疗选择。本研究评估了2012年至2015年间，巴西里约热内卢87名未接受过抗逆转录病毒治疗的HIV-1感染孕妇中，HIV-1 pol基因蛋白酶（PR）和逆转录酶（RT）区域传播耐药性（TDR）的多样性和流行情况。病毒多样性包括HIV-1 B亚型（67.8%）、F1亚型（17.2%）和C亚型（4.6%）；循环重组型12_BF（2.3%）、28/29_BF、39_BF、02_AG（各占1.1%）以及独特重组型（4.5%）。任何TDR的总体流行率为17.2%，其中核苷类逆转录酶抑制剂为5.7%，非核苷类逆转录酶抑制剂为5.7%，蛋白酶抑制剂为8%。该人群中发现的TDR流行率可能会影响标准PMTCT抗逆转录病毒治疗方案的病毒学结局，强化了持续监测的重要性。
